Financial Data and Key Metrics Changes - Biohaven reported net revenue of $136 million for NURTEC ODT in Q3 2021, a 46% increase compared to Q2 2021, bringing cumulative net revenue to approximately $336 million since launch [7][22] - The non-GAAP adjusted net loss for Q3 2021 was $125.1 million, or $1.91 per share, compared to a loss of $159.5 million, or $2.67 per share, for the same period in 2020 [24] - Year-to-date R&D investment for the first nine months of 2021 was $210.6 million, up from $137.6 million in the prior year, reflecting a $73 million increase [25] Business Line Data and Key Metrics Changes - NURTEC ODT achieved a 57% market share in the new-to-brand (NBRx) metric, indicating strong demand for its dual indication [8][22] - The oral CGRP class is outperforming initial launch expectations, with NURTEC ODT becoming the number one migraine treatment in its class [8][30] Market Data and Key Metrics Changes - Pfizer's global revenues were reported at $35.4 billion for Q3 2021, highlighting the potential for collaboration to reach a broader patient base [17] - The collaboration with Pfizer aims to accelerate access to Rimegepant for over 1 billion patients worldwide suffering from migraines [9][10] Company Strategy and Development Direction - The strategic collaboration with Pfizer is designed to leverage Biohaven's neuroscience R&D expertise alongside Pfizer's commercialization capabilities to enhance global access to Rimegepant [6][9] - Biohaven aims to maintain U.S. commercialization rights for NURTEC ODT while partnering with Pfizer for markets outside the U.S., allowing for a focus on global expansion [13][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the collaboration with Pfizer, emphasizing the potential to transform Rimegepant into a global brand and improve patient access [12][15] - The management team highlighted the importance of the dual indication of NURTEC ODT in changing the treatment paradigm for migraine patients [28][30] Other Important Information - Biohaven's cash position is expected to strengthen significantly with Pfizer's upfront investment of $150 million and an additional $350 million equity investment [10][21] - The company has over 45 completed clinical trials and approximately 40 ongoing trials, indicating a robust pipeline for future growth [35][39] Q&A Session Summary Question: Why not a complete exit with Pfizer potentially buying the whole company? - Management believes the current partnership preserves optionality in the U.S. while enhancing future revenue potential and operational capabilities globally [46][47] Question: Clarification on the $740 million in milestones related to the Pfizer deal? - Management indicated that details on the split between regulatory and commercial milestones would be provided in future filings, emphasizing that revenues would be realized sooner than anticipated [50][51] Question: How does NURTEC's profile compare to other CGRP treatments? - Management highlighted that NURTEC is unique as it offers both acute treatment and prevention in one pill, which resonates well with patients and healthcare providers [52][53] Question: Any strategic synergies between Biohaven and Pfizer? - The collaboration is expected to leverage Pfizer's global presence and expertise in primary care to enhance the reach of NURTEC [55][57] Question: How are conversations with payers going for preventive treatment? - Discussions with payers are progressing well, with confidence in maintaining coverage for acute therapy and positive feedback for preventive treatment [66][67] Question: Are there any clauses in the agreement that could prevent future expansions? - Management confirmed there are no standstill clauses in the agreement, allowing for potential future expansions [70][72]

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Q2 2021 Earnings Conference Call August 9, 2021 8:30 AM ET | --- | |--------------------------------------------| | | | Company Participants | | Caroline Dircks - VP, Corporate Operations | | Vlad Coric - CEO | | Jim Engelhart - CFO | | BJ Jones - CCO | | Elyse Stock - CMO | | Conference Call Participants | | Paul Choi - Goldman Sachs | | Ken Cacciatore - Cowen | | Chris Raymond - Piper Sandler | | Charles Duncan - Cantor Fitzgerald | | Laura Chico - ...

Ellie, living with migraine Ellie, living with migraine 2nd Quarter 2021 Earnings August 9, 2021 e NYSE:BHVN © 2021 Biohaven Pharmaceuticals. All rights reserved. Agenda Opening Remarks | Caroline Dircks, Ph.D. Vice President Corporate Operations Second Quarter Summary and Recent Events| Vlad Coric, M.D. Chief Executive Officer 2Q2021 Financial Results | Jim Engelhart, C.P.A. Chief Financial Officer Commercial Events | BJ Jones, M.B.A. Chief Commercial Officer Migraine and Common Disease R&D Update | Elyse ...

Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Q1 2021 Results Conference Call May 10, 2021 8:30 AM ET Company Participants Clifford Bechtold - Chief Operating Officer Vladimir Coric - Chief Executive Officer Jim Engelhart - Chief Financial Officer BJ Jones - Chief Commercial Officer Dr. Elyse Stock - Chief Medical Officer Conference Call Participants Kenneth Cacciatore - Cowen and Company Kyuwon Choi - Goldman Sachs Group Christopher Joseph - Raymond Piper Sandler Laura Kathryn - Wedbush Securitie ...

Financial Data and Key Metrics Changes - Nurtec ODT achieved fourth quarter net revenues of approximately $35 million, representing an increase of over 98% from the third quarter [7][27] - Non-GAAP adjusted net loss for Q4 2020 was $161.7 million or $2.69 per share, compared to a loss of $124.4 million or $2.38 per share for the same period in 2019 [29] - Cash, marketable securities, and restricted cash totaled $357.4 million as of December 31, 2020, with immediate access to an additional $225 million from a debt facility [30] Business Line Data and Key Metrics Changes - Nurtec ODT has achieved over 450,000 prescriptions with more than 89% commercial coverage [7][8] - SG&A expenses for Q4 2020 on a non-GAAP basis were $114 million, an increase of $47.2 million from the prior year, reflecting investments in the launch of Nurtec [28] Market Data and Key Metrics Changes - The oral CGRP class is experiencing rapid growth, with Nurtec positioned to capture a significant share of the market [34] - Approximately 96% of neurologists perceive Nurtec ODT as an advancement over triptans, with nearly half anticipating it as their preferred acute migraine therapy [35] Company Strategy and Development Direction - The company aims to maximize patient and shareholder value by executing on the Nurtec launch and expanding its indications to include prevention of migraine and other pain-related disorders [9][10] - Biohaven is focused on establishing Nurtec as the first dual-acting migraine therapy for both acute and preventive treatment in one pill, aiming to simplify the treatment paradigm [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future growth of Nurtec, anticipating continued market expansion and multiple pivotal trial readouts over the next year [60] - The company is preparing for a potential FDA decision on the approval of Nurtec for prevention by the end of Q2 2021 [42] Other Important Information - Biohaven's pipeline includes intranasal zavegepant, which is expected to file as the first intranasal CGRP antagonist for ultra-rapid treatment of migraine [23] - The company is also exploring non-migraine indications, including psoriasis and asthma, as part of its CGRP franchise expansion [47] Q&A Session Summary Question: Current situation with Nurtec in terms of persistence - Management indicated that refill rates for Nurtec align with expected usage based on migraine frequency, supporting the prevention strategy [64] Question: Insights on sNDA for prevention and EMEA filing - Management noted that they have not received negative comments from the mid-cycle review, which is seen as encouraging for the dual-acting indication in Europe [66] Question: Trends in sales force engagement and authorizations - Management reported that clinician offices are reopening, leading to increased patient access and engagement, which is expected to positively impact sales [70] Question: Impact of patient deductibles and reauthorizations on Q1 - Management explained that the reset of patient deductibles and prior authorizations is a standard occurrence at the beginning of the year, affecting gross-to-net dynamics [76] Question: Lifecycle extension indications for Nurtec - Management expressed excitement about lifecycle management opportunities, including pediatric indications, which are expected to provide significant upside potential [88]

March 1, 2021 4th Quarter 2020 Earnings Ellie, living with migraine © 2021 Biohaven Pharmaceuticals. All rights reserved. NYSE:BHVN Agenda Opening Remarks | Cliff Bechtold, M.S. Chief Operating Officer Quarter Summary and Year in Review | Vlad Coric, M.D. Chief Executive Officer 4Q20 and 2020 Year-End Financial Results | Jim Engelhart, C.P.A. Chief Financial Officer Commercial Events | BJ Jones, M.B.A. Chief Commercial Officer Migraine and Common Disease R&D Update | Elyse Stock, M.D. Chief Medical Officer ...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants | --- | |------------------------------------------| | | | Cliff Bechtold - Chief Operating Officer | | Vlad Coric - Chief Executive Officer | | Jim Engelhart - Chief Financial Officer | | BJ Jones - Chief Commercial Officer | | Elyse Stock - Chief Medical Officer | | Conference Call Participants | | Paul Choi - Goldman Sachs | | Tyler Van Buren - Piper Sandler | | Ken C ...

Ellie, living with migraine 3rd Quarter 2020 Earnings November 9, 2020 © 2020 Biohaven Pharmaceuticals. All rights reserved. NYSE:BHVN Cliff Bechtold, M.S. | Chief Operating Officer Opening Remarks Agenda 3 Opening Remarks | Cliff Bechtold, M.S. Chief Operating Officer Quarter Summary and Recent Events | Vlad Coric, M.D. Chief Executive Officer 3Q20 Financial Results | Jim Engelhart, C.P.A. Chief Financial Officer Commercial Events | BJ Jones, M.B.A. Chief Commercial Officer Migraine and Common Disease R&D ...

Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Q2 2020 Earnings Conference Call August 10, 2020 8:00 AM ET Company Participants Clifford Bechtold - COO Vladimir Coric - CEO & Director James Engelhart - CFO & Treasurer William Jones - Chief Commercial Officer, Migraine & Common Diseases Elyse Stock - Chief Medical Officer Conference Call Participants Paul Choi - Goldman Sachs Group Charles Duncan - Cantor Fitzgerald & Co. Ken Cacciatore - Cowen and Company Laura Chico - Wedbush Securities Timothy Lu ...

neuroinnovation Meeting Patient Needs Growing Value INVESTOR PRESENTATION | AUG 2020 NYSE: BHVN © 2020 Biohaven Pharmaceuticals Inc. All rights reserved. Disclaimer This presentation contains forward-looking statements within the meaning of "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995, including: statements about Biohaven Pharmaceutical Holding Company Ltd. (The "Company") and our plans to develop and commercialize our product candidates, our planned clinical trials for o ...